BENEVOLENTAI DRUG PIPELINE
UC affects 0.2% of the US population.(1)
20-40% of moderate-severe patients do not respond to anti-TNF therapy, a key treatment approach.(2)
The only oral treatment option currently available has serious side effects.(3)
$8.1bn–$14.9bn annual direct and indirect costs estimated in the US alone.(4)
"For our two UC programmes, we identified and validated an AI-generated target with novel mechanisms of action in UC, and also used AI-chemistry to rapidly move an asset through Hit Identification, Hit Expansion and Lead Optimisation. Candidate drugs are expected a little over 2 years from the programme’s inception."
(1) Ulcerative Colitis: Epidemiology Forecast to 2029 - GlobalData Report Store, 2021. [Accessed April 2021]
(2) Roda, G et al. Loss of Response to Anti-TNFs: Definition, Epidemiology, and Management. Clin Transl Gastroenterol. 2016 Jan; 7(1): e135. doi: 10.1038/ctg.2015.63
(3) U.S. Food & Drug Administration. Initial safety trial results find increased risk of serious heart-related problems and cancer with arthritis and ulcerative colitis medicine Xeljanz, Xeljanz XR (tofacitinib). 2021. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/initial-safety-trial-results-find-increased-risk-serious-heart-related-problems-and-cancer-arthritis [Accessed April 2021].
(4) Cohen, R.D et al. Systematic review: The costs of ulcerative colitis in Western countries. Aliment. Pharmacol. Ther. 2010, 31, 693–707.